» Articles » PMID: 32868629

Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers

Abstract

Introduction: Sustained high alcohol intake is necessary but not sufficient to produce alcohol-related cirrhosis. Identification of risk factors, apart from lifetime alcohol exposure, would assist in discovery of mechanisms and prediction of risk.

Methods: We conducted a multicenter case-control study (GenomALC) comparing 1,293 cases (with alcohol-related cirrhosis, 75.6% male) and 754 controls (with equivalent alcohol exposure but no evidence of liver disease, 73.6% male). Information confirming or excluding cirrhosis, and on alcohol intake and other potential risk factors, was obtained from clinical records and by interview. Case-control differences in risk factors discovered in the GenomALC participants were validated using similar data from 407 cases and 6,573 controls from UK Biobank.

Results: The GenomALC case and control groups reported similar lifetime alcohol intake (1,374 vs 1,412 kg). Cases had a higher prevalence of diabetes (20.5% (262/1,288) vs 6.5% (48/734), P = 2.27 × 10-18) and higher premorbid body mass index (26.37 ± 0.16 kg/m2) than controls (24.44 ± 0.18 kg/m2, P = 5.77 × 10-15). Controls were significantly more likely to have been wine drinkers, coffee drinkers, smokers, and cannabis users than cases. Cases reported a higher proportion of parents who died of liver disease than controls (odds ratio 2.25 95% confidence interval 1.55-3.26). Data from UK Biobank confirmed these findings for diabetes, body mass index, proportion of alcohol as wine, and coffee consumption.

Discussion: If these relationships are causal, measures such as weight loss, intensive treatment of diabetes or prediabetic states, and coffee consumption should reduce the risk of alcohol-related cirrhosis.

Citing Articles

MetALD: Clinical aspects, pathophysiology and treatment.

Gratacos-Gines J, Arino S, Sancho-Bru P, Bataller R, Pose E JHEP Rep. 2025; 7(2):101250.

PMID: 39897615 PMC: 11782861. DOI: 10.1016/j.jhepr.2024.101250.


Alcohol Use Disorder and Alcohol-Associated Liver Disease: New Definitions, Screening, and Treatment.

Roldan G, Tricarico C, Brown Jr R Gastroenterol Hepatol (N Y). 2025; 20(11):662-671.

PMID: 39886332 PMC: 11775998.


Cell-to-cell and organ-to-organ crosstalk in the pathogenesis of alcohol-associated liver disease.

Gao H, Jiang Y, Zeng G, Huda N, Thoudam T, Yang Z eGastroenterology. 2024; 2(4).

PMID: 39735421 PMC: 11674000. DOI: 10.1136/egastro-2024-100104.


History of toxicology at the Technical University of Munich (TUM).

Greim H Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9597-9602.

PMID: 39046531 PMC: 11582189. DOI: 10.1007/s00210-024-03315-0.


Combined impact of alcohol consumption and metabolic syndrome on liver dysfunction in an elderly Chinese population.

Zhao Y, Yuan X, Lin T, Yang Q, Jiang X, Yang S Diabetol Metab Syndr. 2024; 16(1):74.

PMID: 38519973 PMC: 10960482. DOI: 10.1186/s13098-024-01312-0.